Key Points
- Insider sale: Director Dianne Whitfield sold 7,397 shares on Dec. 16 at an average price of $80.10 for about $592,500, trimming her stake by 15.96% to 38,958 shares (≈$3.12M).
- Company performance: Tarsus (market cap ~$3.29B) opened at $77.48, has a 12‑month range of $38.51–$85.25, and reported revenue of $118.7M (beat estimates) but remains unprofitable (EPS -$0.30, negative margins and ROE).
- Analyst backdrop: Consensus is a "Moderate Buy" with a $79.86 price target, though analyst opinions vary from a Weiss "sell (D-)" to multiple buy/overweight ratings and price targets up to $100.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 7,397 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the transaction, the insider directly owned 38,958 shares in the company, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Tarsus Pharmaceuticals Stock Performance
Shares of Tarsus Pharmaceuticals stock opened at $77.48 on Friday. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -38.36 and a beta of 0.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The business has a 50-day moving average of $74.91 and a 200 day moving average of $57.82. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The business had revenue of $118.70 million for the quarter, compared to analysts' expectations of $114.22 million. As a group, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms have issued reports on TARS. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. Guggenheim upped their price objective on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. Barclays started coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an "overweight" rating and a $100.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a report on Wednesday, October 8th. Finally, Mizuho began coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They set an "outperform" rating and a $100.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $79.86.
View Our Latest Stock Report on TARS
Hedge Funds Weigh In On Tarsus Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of TARS. CIBC Bancorp USA Inc. acquired a new stake in Tarsus Pharmaceuticals in the third quarter valued at $248,000. Voleon Capital Management LP acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $1,366,000. Quarry LP increased its holdings in shares of Tarsus Pharmaceuticals by 103.3% in the 3rd quarter. Quarry LP now owns 6,100 shares of the company's stock valued at $363,000 after acquiring an additional 3,100 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Tarsus Pharmaceuticals by 13.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 522,276 shares of the company's stock worth $31,039,000 after acquiring an additional 62,840 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in Tarsus Pharmaceuticals by 73.0% during the third quarter. Millennium Management LLC now owns 100,568 shares of the company's stock worth $5,977,000 after purchasing an additional 42,427 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
